Anti-CGRP therapies for migraine in multiple sclerosis patients

Mult Scler. 2022 Nov;28(13):2149-2150. doi: 10.1177/13524585221096353. Epub 2022 May 14.

Authors

Alicia Gonzalez-Martinez¹, Gauruv Bose^{1

2}, Tanuja Chitnis^{1

2}

Affiliations

¹ Translational Neuroimmunology Research Center (TNRC), Ann Romney Center for Neurologic Diseases (ARCND), Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA.
² Brigham Multiple Sclerosis Center, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

PMID: 35575242
DOI: 10.1177/13524585221096353

No abstract available

Publication types

Letter
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal
Humans
Migraine Disorders* / drug therapy
Multiple Sclerosis* / complications
Multiple Sclerosis* / drug therapy

Substances

Antibodies, Monoclonal